IP Library Granted Patent US 11,357,799
Granted Patent B2
US 11,357,799 · App. 15/516,658 · Granted Jun 14, 2022

Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy

Inventors: Eduardo Marban (Santa Monica, CA); Mark Amin Aminzadeh (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center
A61K35/34A61K9/0019A61K31/713A61K38/1709A61P9/10A61P21/00C12N15/113C12N2310/141C12N2320/31C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,799
App. No.
15/516,658
Granted
Jun 14, 2022
Kind
B2
Abstract

Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cell-free” therapeutic candidate for tissue repair.

Claims (8)

1. A method of treating heart failure secondary to muscular dystrophy, comprising:

administering a composition comprising cardiosphere-derived cells (CDCs) to a subject in need of treatment for heart failure secondary to muscular dystrophy, wherein administration of the composition treats the subject.

2. The method of claim 1 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

3. The method of claim 1 , wherein administering a composition comprises about 1×10 5 to about 1×10 8 or more CDCs in a single dose.

4. The method of claim 3 , wherein administering a composition comprises myocardial infusion.

5. The method of claim 4 , wherein myocardial infusion is intracoronary.

6. The method of claim 4 wherein myocardial infusion is intra-arterial or intravenous.

7. The method of claim 1 , wherein treatment of the subject results in decreased fibrosis, decreased inflammation, increased mitochondrial function and/or increased cardiomyogenesis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 14, 2018
From: CEDARS-SINAI MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045594/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2017
From: MARBAN, EDUARDO; AMINZADEH, MARK AMIN
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 043002/0762 →
Continuity (2)
Provisional Application 62059308 · Oct 3, 2014
Related Publication 20170290860A1 · Oct 12, 2017
Cited By (2)
US 12,544,409 US 12,584,127